Produced in partnership with
The Society for
Cardiac Angiography and Interventions 
www.scai.org

Welcome!

SCAI is pleased to announce the formation of an e-learning partnership with MEBN.NET, a leading publisher of accredited CME programs.

Together, SCAI and MEBN.NET bring you an innovative series of live, interactive web events that provide you with the latest in clinical topics, best practice recommendations, and treatment options. These educational sessions are presented by the foremost thought leaders in cardiac catheterization and angiography and are free to member of SCAI.

eDebate:
Renal stenting: Do we need another trial?

Recorded on:
Wednesday, September 3, 2003

[More...]

These events are produced in partnership with SCAI and MEBN.net and are free for SCAI members thanks to a generous grant from Pfizer.

Highlights from the Melvin P. Judkins 2003 Cardiac Imaging Symposium:

These programs include cutting edge presentations, review of recent trials, lectures, interactive workshops, cine review sessions, symposia, and abstract presentations describing original work. The featured speakers and faculty are national and international leaders and teachers of invasive and interventional cardiology.. [View Recordings]

These events are produced in partnership with SCAI and MEBN.net and are free for SCAI members thanks to a generous grant from Pfizer.

Masters in Medicine: Optimal Anticoagulation Strategies for Percutaneous Intervention

Recorded on:
Thursday, March 27, 2003

Join us for Masters in Medicine: Optimal Anticoagulation Strategies for Percutaneous Intervention, a panel discussion about the adjunct use of potent antithrombotic agents in PCI with Frederick Feit, MD; David Moliterno, MD; and Steven R. Steinhubl, MD. [View Recording]

These events are produced in partnership with SCAI and MEBN.net and are free for SCAI members thanks to a generous grant from Pfizer.

Drug-Eluting Stents:
Will Cost Constraints Affect Their Wide Use?

Recorded on:
Thursday, February 20, 2003

Healthcare providers find themselves in a constant tug-of-war between providing quality care and managing costs. This struggle is often greatest during the introduction of new technologies. It is predicted that by 2005, the use of these stents could reduce surgery by almost 50%, cause significant reductions of medical therapy, and increase the frequency of intervention procedures for coronary artery disease. Although the use of drug-eluting stents brings promise of improved outcomes for cardiology patients, it also poses an economic impact. For example, cardiologists must be aware of the high cost of these devices and the impact of their use on the patient's financial and medical insurance resources.
[View Recording]

These events are produced in partnership with SCAI and MEBN.net and are free for SCAI members thanks to a generous grant from Pfizer.